To include your compound in the COVID-19 Resource Center, submit it here.

Alnylam switching to backup AAT molecule after safety signal

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) said it will discontinue development of ALN-AAT for alpha-1 antitrypsin (AAT; A1AT; SERPINA1) deficiency-associated

Read the full 182 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE